Incyte (INCY) Revenue — Quarter Ended Jun 30, 2025
Revenue for the quarter increased compared to the prior quarter and the same quarter last year. The company's filing highlights ongoing patent challenges and generic competition for its key product JAKAFI.
Key takeaway
Quarter ended Jun 30, 2025 · FY2025 Q2
Revenue for the quarter increased compared to the prior quarter and the same quarter last year. The company's filing highlights ongoing patent challenges and generic competition for its key product JAKAFI.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$1.2B
Revenue reported for this quarter.
Quarter-over-quarter
+15.4%
Change from the immediately preceding quarter.
Year-over-year
+16.5%
Change from the comparable year-ago quarter.
Trailing four quarters
$4.6B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Sep 30, 2024 | $1.1B | +23.8% |
| Dec 31, 2024 | $1.2B | +16.3% |
| Mar 31, 2025 | $1.1B | +19.5% |
| Jun 30, 2025 | $1.2B | +16.5% |
Revenue performance
Reported revenue was higher than the immediately preceding quarter and also higher than the same quarter one year earlier. The quarter's performance reflects a continued upward trend in revenue.
Quarterly comparison
Compared with the prior quarter, revenue increased, and versus the same quarter a year ago, revenue also rose. These comparisons indicate a positive year-over-year and sequential improvement.
What to watch
The filing discusses patent litigation and generic entry attempts for JAKAFI, which could affect future revenue if successful.